|Day Low/High||137.47 / 138.82|
|52 Wk Low/High||118.62 / 148.99|
I find a lot of Reuters' claims hard to believe. Even more difficult to believe is the selloff.
Many analysts advise buying the shares on weakness because it's attractively priced.
JNJ ended the day and week in a vulnerable position and we are seeing further weakness today.
The market appears to still be spooked by JNJ as shares are set to open at their lowest level since July amid the Reuters articles fallout.
Now the unnerving thing about this market is that when it gets on a negative roll it blows through all convention.
While headline-chasing algorithms alter expected outcomes based on fundamental analysis, technical analysis remains valid.
Johnson & Johnson has survived some unfortunate news events in the past, but I would not take that as a good technical reason to hold the stock.
Unimpressed Equity markets headed lower as the regular Friday trading session extended into it's second and third hours. The way down has been led, not by Adobe , not by Costco , but by Johnson & Johnson . I have been known to make limited attempts ...
Use it to your advantage or don't use it at all.
It's done without much thought even though their companies are doing amazingly well.
Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?
With all the major indices trading below 50-day moving averages, it would take a big move up to be meaningful.
Pfizer pushes higher on price increases.
A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
These are simply programs where some ETFs and handcrafted baskets are overwhelming both sides of the market.
This is what the market looks like when the Fed says nothing and the president isn't ranting about something.
This is a battleground stock that has made big moves in both directions on earnings in the past.
Adobe released new guidance for the rest of this year and 2019. With 20% growth in the cards, this name is a buy.
The DJIA is not accurately reflecting what's going on in the market and will cause you to miss broader weakness that has taken hold.
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
The answer is plenty, but you can't trade that.
Let's check some updated charts to see if our strategy is still on track.
As many are aware...I am a believer that in a sea of green, stocks that are red are short trading candidates over the very short term. Conversely, in a sea of red, stocks that are green are long trading candidates over the very near term. Following ...